Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial

被引:4
作者
Hermanns, Norbert [1 ,2 ,3 ]
Ehrmann, Dominic [1 ,3 ]
Finke-Groene, Katharina [1 ]
Krichbaum, Michael [1 ]
Roos, Timm [1 ]
Haak, Thomas [2 ]
Freckmann, Guido [4 ]
Kulzer, Bernhard [1 ,2 ,3 ]
机构
[1] Res Inst Diabet Acad Mergentheim FIDAM, Johann Hammer Str 24, D-97980 Bad Mergentheim, Germany
[2] Diabet Ctr Bad Mergentheim, Theodor Klotzbucherstr 12, D-97980 Bad Mergentheim, Germany
[3] Univ Bamberg, Dept Clin Psychol & Psychotherapy, Markuspl 3, D-96047 Bamberg, Germany
[4] IfDT Inst Diabet Technol Forsch & Entwicklungsgese, Helmholtzstr 20, D-89081 Ulm, Germany
来源
LANCET REGIONAL HEALTH-EUROPE | 2023年 / 33卷
关键词
Type; 2; diabetes; Basal insulin; Insulin titration; Digital health tool; Titration app; My Dose Coach app; CLINICAL INERTIA; THERAPY;
D O I
10.1016/j.lanepe.2023.100702
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background The majority of people with type 2 diabetes who require insulin therapy use only basal insulin in combination with other anti-diabetic agents. We tested whether using a smartphone application to titrate insulin could improve glycaemic control in people with type 2 diabetes who use basal insulin.Methods This was a 12-week, multicentre, open-label, parallel, randomised controlled trial conducted in 36 diabetes practices in Germany. Eligible participants had type 2 diabetes, a BMI >= 25.0 kg/m(2), were on basal insulin therapy or were initiating basal insulin therapy, and had suboptimal glycaemic control (HbA1c >7.5%; 58.5 mmol/mol). Block randomisation with 1:1 allocation was performed centrally. Participants in the intervention group titrated their basal insulin dose using a smartphone application (My Dose Coach) for 12 weeks. Control group participants titrated their basal insulin dose according to a written titration chart. The primary outcome was the baseline-adjusted change in HbA1c at 12 weeks. The intention-to-treat analysis included all randomised participants.Results Between 13 July 2021 and 21 March 2022, 251 study participants were randomly assigned (control group: n = 123; intervention group: n = 128), and 236 completed the follow-up phase (control group: n = 119; intervention group: n = 117). Regarding the HbA1c a model-based adjusted between-group difference of -0.31% (95% CI: 0.01%-0.69%; p = 0.0388) in favour of the intervention group was observed. There were 30 adverse events reported: 16 in the control group, 14 in the intervention group. Of these, 15 adverse events were serious. No event was considered to be related to the investigational device.Interpretation Study results suggest that utilizing this digital health smartphone application for basal insulin titration may have resulted in a comparatively greater reduction in HbA1c levels among individuals with type 2 diabetes, as compared to basal insulin titration guided by a written titration schedule. No negative effect on safety outcomes was observed.
引用
收藏
页数:12
相关论文
共 31 条
  • [1] [Anonymous], 2021, IDF DF diabetes atlas 2021, V10th
  • [2] Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial)
    Bajaj, Harpreet S.
    Venn, Karri
    Ye, Chenglin
    Aronson, Ronnie
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (10) : 610 - 615
  • [3] The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-Centered Multidisciplinary Diabetes Program (the NADIR Study)
    Bajaj, Harpreet S.
    Aronson, Ronnie
    Venn, Karri
    Ye, Chenglin
    Sharaan, Maha E.
    [J]. CANADIAN JOURNAL OF DIABETES, 2016, 40 (02) : 120 - 125
  • [4] Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis
    Basu, Sanjay
    Yudkin, John S.
    Kehlenbrink, Sylvia
    Davies, Justine I.
    Wild, Sarah H.
    Lipska, Kasia J.
    Sussman, Jeremy B.
    Beran, David
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (01) : 25 - 33
  • [5] A Smartphone Application to Deliver a Treat-to-Target Insulin Titration Algorithm in Insulin-Naive Patients With Type 2 Diabetes: A Pilot Randomized Controlled Trial
    Bee, Yong Mong
    Batcagan-Abueg, Ada Portia M.
    Chei, Choy-Lye
    Do, Young Kyung
    Haaland, Benjamin
    Goh, Su-Yen
    Lee, Phong Ching
    Chiam, Priscilla Pei Sze
    Ho, Emily Tse Lin
    Matchar, David B.
    [J]. DIABETES CARE, 2016, 39 (10) : E174 - E176
  • [6] Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial
    Bergenstal, Richard M.
    Johnson, Mary
    Passi, Rebecca
    Bhargava, Anuj
    Young, Natalie
    Kruger, Davida F.
    Bashan, Eran
    Bisgaier, Stanley G.
    Isaman, Deanna J. Marriott
    Hodish, Israel
    [J]. LANCET, 2019, 393 (10176) : 1138 - 1148
  • [7] Bergis N., 2012, Diabetol Stoffwechs, V7, P9
  • [8] Bergis-Jurgan N, 2013, Diabetol Stoffwechs, V8, P134
  • [9] Testing and standardization of the German version of the EUROHIS-QOL and WHO-5 quality-of life-indices
    Braeher, Elmar
    Muehlan, Holger
    Albani, Cornelia
    Schmidt, Silke
    [J]. DIAGNOSTICA, 2007, 53 (02): : 83 - 96
  • [10] Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review
    Davies, M. J.
    Gagliardino, J. J.
    Gray, L. J.
    Khunti, K.
    Mohan, V.
    Hughes, R.
    [J]. DIABETIC MEDICINE, 2013, 30 (05) : 512 - 524